US 7,332,526 B2
	Compositions and methods comprising prostaglandin-related compounds and trefoil factor family peptides for the treatment of glaucoma with reduced hyperemia
Peter G. Bakhit, Huntington Beach, Calif. (US); Richard Graham, Irvine, Calif. (US); and Orest Olejnik, Coto de Caza, Calif. (US)
Assigned to Allergan, Inc., Irvine, Calif. (US)
Filed on Jun. 12, 2007, as Appl. No. 11/761,498.
Application 11/761498 is a continuation of application No. 10/521367, granted, now 7,244,768, previously published as PCT/US2004/027777, filed on Aug. 25, 2004.
Claims priority of provisional application 60/508445, filed on Oct. 03, 2003.
Prior Publication US 2007/0244051 A1, Oct. 18, 2007
Int. Cl. A01N 31/00 (2006.01); A61K 38/00 (2006.01)

U.S. Cl. 514—738  [514/13]

14 Claims

1. A dosage form comprising a prostaglandin and a trefoil factor family peptide wherein the prostaglandin is latanoprost and the trefoil factor family peptide is selected from the group consisting of TFF1 and TFF3.